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response (PR) or stable disease (SD)) and local tumor control. 
Indices of SUVmax in tumors/SUVmean in muscle were 
calculated for individual patients. Normalized SUV FDG 
(SUVmax tumor/SUV mean muscle) was plotted against 
normalized baseline SUV F-MISO1 (SUVmax tumor/SUV mean 
muscle) and the correlation was calculated. Follow-up 
included MRI every 3 months. 
Results: Patients undergoing definitive RCTx for SCCHN 
(n=16) were included. Tumor hypoxia was present in >90% of 
patients at baseline whereas at subsequent examinations 
hypoxia was sharply diminished in incidence (36% and 27%) 
and extent. On quantitative analysis the mean SUVmax 
indices decreased from 1.9 (week 0) to 1.6 (week 2) and 1.3 
(week 5). No correlation was found for normalized SUV FDG 
and the corresponding normalized baseline SUV F-MISO1 
(Pearson correlation coefficient 0.32). MRI scans obtained at 
treatment week 5 showed CR in 8 %, PR in 77 % and SD in 15 
% of patients. Kaplan-Meier analysis of local recurrence 
against time after treatment for a mean follow up of 39 
months showed significantly worse local tumor control for 
tumors hypoxic on F-MISO PET 1 and 2 (p<0.05) compared to 
non-hypoxic-tumors. 
Conclusions: Stable reduction of tumor hypoxia was found in 
the majority of patients. A significant correlation between 
tumor hypoxia obtained by F-MISO PET (F-MISO 1, 2) and local 
control was found.  
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Purpose/Objective: Radiotherapy (RT) for non-small cell lung 
cancer (NSCLC) may cause late toxicities, such as heart 
toxicity, changes in pulmonary function (PF) and lung 
fibrosis, but late toxicity data are scarce in the literature for 
this category of patients. The objective of this study was to 
analyze long term PF changes after definitive RT for patients 
with NSCLC. PF was measured by FEV1 and FVC as assessed by 
spirometry.  
Materials and Methods: This is a single institution study of 
patients receiving definitive RT for NSCLC between 1996 and 
2010. A total of 556 consecutive treated patients with 3063 
pairs of pulmonary function test (PFTs) were screened for 
eligibility for inclusion in the analysis of late changes in PF. 
To be eligible, patients had at least 3 PFTs after baseline. In 
this study, baseline was defined as 12 months after RT 
commencement to overcome a possible effect of tumor 
shrinkage and the acute side effect, radiation induced 
pneumonitis. PFT within 6 months prior to thoracic 
progression were excluded. The final study group comprised 
106 patients with 1286 pairs of PFTs. For each patient 
complete dosimetric data, including GTV, PTV, mean lung 
dose, Vx for total lung volume were available as well as 
patient specific pretreatment factors such as age, gender, 
smoking status, performance status, and pretreatment PF. 
Multivariable regression analyses were performed with 
patient, treatment, and dose-volume metrics as covariates to 
investigate their possible impact on long term PF. FEV1 and 
FVC were analyzed separately. 
Results: The long-term change in PF relative to the 1-year 
baseline was estimated by linear regression. Relative to the 
1-year-FEV1 most patients experienced a decrease in FEV1 
over time. The change in FEV1 per year, varied considerably 
among patients (Fig 1). Treatment year and V60 were the only 
covariates having a significant impact on FEV1 deterioration. 
Patients treated early in the period experienced a larger 
functional decline. Also for FVC a linear relationship with the 
follow-up time was found, again with large inter-patient 
variation. An unsuspected finding was that high V60 was 
associated with less decline in FVC, but FVC may be a less 
reliable parameter for pulmonary damage. 
 
Figure 1. Data on pulmonary function expressed in FEV1 from 
2 patients.The straight lines are the estimated loss, λ in the 
model. Zero denotes baseline, i.e. 12 months after start of 
radiotherapy. 
Conclusions: Patients experience a decline in FEV1 after the 
12-month value following definitive RT for NSCLC. In a 
multivariable analysis, deterioration of FEV1 was significantly 
associated with V60 of the lung (risk factor) and treatment 
year (risk factor). Early calendar year of treatment was 
associated with higher risk of deterioration. The yearly 
decline in FVC was less than in FEV1. A large V60 was, 
somewhat puzzling, associated with a lower FVC decline in a 
multivariable analysis. 
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Purpose/Objective: The state of oligometastases was divided 
into sync-oligometastases and oligo-recurrence, the 
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difference being that the primary site of oligometastases was 
uncontrolled (sync-oligometastases) or controlled (oligo-
recurrence). The goal of this multicenter study was to 
evaluate treatment outcomes and to evaluate factors 
affecting relapse-free survival (RFS) after stereotactic body 
radiotherapy (SBRT) for pulmonary oligometastases. 
Materials and Methods: A total of 96 patients (65 males and 
31 females) who received SBRT for oligometastatic lung 
tumors between January 2004 and April 2014 at 4 high-
volume institutions in Japan were enrolled in this 
retrospective study. The primary sites were the colorectum 
(n=25), lung (n=24), head and neck (n=8), uterus (n=8) and 
others (n=31), and the pathologies of primary cancers were 
adenocarcinoma (n=49), squamous cell caricinoma (n=19), 
others (n=12) and pathologically unproven (n=16). The 
median tumor diameter was 19 mm (range, 6-42 mm). Ten 
cases were sync-oligometastases and 79 cases were oligo-
recurrences. The median disease-free interval (DFI) between 
initial therapy and SBRT was 24 months (range, 0-246 
months). The median calculated biological effective dose was 
105.6 Gy (range, 75-134.4 Gy) using the LQ model with 
alpha/beta = 10 Gy. The prescribed dose was delivered to the 
isocenter (n=56) or covering 95% of the PTV (D95, n=40). 
Cumulative overall survival (OS), local control rate (LCR) and 
RFS rate were calculated using Kaplan-Meier curves, and the 
log-rank test was used to compare the curves. Multivariate 
analysis for RFS was performed using a Cox proportional 
hazards model. Statistical significance was defined as a value 
of p < 0.05 in this study. 
Results: The median follow-up periods were 21 months 
(range, 1-119 months) for all patients and 32 months (range, 
1-119 months) for survivors. The 3-year OS, LCR and RFS rates 
were 52%, 75% and 25%, respectively. Radiation pneumonitis 
of grade 3 was found in 2 patients and gastrointestinal 
toxicity of grade 4 was found in 1 patient. No grade 5 toxicity 
occurred. The 3-year RFS for sync-oligometastases was 0% 
and that for oligo-recurrence was 28% (Figure, p < 0.01). The 
3-year RFS for the subgroup of DFI < or = 24 months and that 
for the subgroup of DFI > 24 months were 17% and 34%, 
respctively (p = 0.01). In multivariate analysis, sync-
oligometastases (p = 0.01), multiple oligometastatic tumors 
(p = 0.01) and D95 (p = 0.02) were significantly unfavorable 
factors for RFS. 
 
 
 
Conclusions: In SBRT for oligometastatic lung tumors, control 
of the primary site is a significant prognostic factor for RFS. 
Single oligo-recurrence tumor in the lung could be a good 
candidate for SBRT.  
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Purpose/Objective: In the multicenter PET-Plan study, which 
is comparing FDG–PET based treatment planning for 
chemoradiotherapy of NSCLC with conventional target 
volumes in terms of loco-regional progression the cardiac 
dose is an important planning criterion. The presented study 
examines the extent of deviation of delineated heart 
contours from two study centers compared to the per- 
rotocol delineation and its effect on the heart dose with 
particular consideration of the dose distribution. 
Materials and Methods: Heart contours from 59 patients of 
two study centers were re-delineated in strict adherence to 
the study protocol (starting just below the level in which the 
pulmonary trunk branches into the left and right PA, ending 
where the heart blends with the diaphragm). The volumes 
and dose values of the original contours of both centers were 
compared with the values resulting from the protocol-
compliant delineation with Student's t - test. 
Results: The original heart contours of the centers were too 
small in every case compared to the respected protocol 
specification [684,10 ± 302,37 cm3 versus 868,18 ± 219,97 
cm3]. The difference was highly significant with 
p=1.267*10-14. The heart dose-volume parameters of the 
original study center contours were compared with the 
results from the protocol-oriented delineation values, 
significantly smaller (Dmax: p=0,00068; V5:  p=0,00013; 
V40: p=3,4*10-9). In three cases, the study protocol’s 
restriction (V40 ≤ 50 %) was exceeded after correct 
delineation of the heart with a percentage of 54,55%, 60,12% 
respectively 58,04%. 
Conclusions: Incorrect delineation of the heart can lead to a 
misinterpretation of the actual organ dose. In individual 
cases this can be associated with the presumption that 
specific dose restrictions are met, even though dose limits 
are already exceeded. 
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Purpose/Objective: To evaluate the feasibility and efficacy 
of simultaneous integrated boost intensity-modulated 
radiation therapy (SIB-IMRT) in patients with limited-disease 
small cell lung cancer (LD-SCLC). 
Materials and Methods: Patients with LD-SCLC were treated 
with SIB-IMRT within 1 week after completion of 2 cycles of 
induction chemotherapy. Then 2-4 cycles of adjuvant 
chemotherapy were administered within 1 week after SIB-
IMRT. Irradiation was given accelerated hyper-fractionated 
with the prescribed dose 57 Gy at 1.9 Gy twice daily to the 
